Basaglar and Lantus - What is the difference between them?
Basaglar and Lantus are both injections that contain insulin glargine, a long-acting form of insulin to help control blood sugar levels in type 1 and type 2 diabetes. They start to work several hours after injection and keep working steadily over a 24 hour period. Lantus was the original insulin glargine, approved in 2000 and is made by Sanofi Aventis. Basaglar, from Eli Lilly, is a "follow on" insulin to Lantus and was approved in 2015.
Lantus and Basaglar are typically administered once daily as an injection given under the skin (subcutaneously). Dosing is determined individually by your doctor.
Basaglar and Lantus are both used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. They are not used to treat diabetic ketoacidosis.
Brand name products that contain insulin glargine:
Soliqua 100/33 is a combination long-acting diabetes injection that contains insulin glargine and lixisenatide, a glucagon-like peptide-1 (GLP-1) agonist.
Is Basaglar a biosimilar to Lantus?
The FDA does not consider Basaglar a biosimilar or generic to Lantus. Basaglar and Lantus are not consider biosimilars because of complicated manufacturing processes and the fact that Lantus is not considered a reference product. They cannot be automatically substituted for one another by your pharmacist. If you have been prescribed Lantus but decide you now want to change to Basaglar, contact your doctor for a new prescription.
Basaglar and Lantus are both equally effective at lowering blood sugar in patients with diabetes and they are identical structurally. Clinical studies conducted by the manufacturer showed that Basaglar is safe, effective and similar to Lantus, so you can feel comfortable using either product. You and your doctor may decide between these insulins based on your health insurance plan coverage, cost, and availability in your area.
Compare prices: Drugs.com Prices, Coupons and Patient Assistance Programs
Basaglar is considered a "follow-on" product to Lantus. The FDA did not approve Basaglar as a biosimilar to Lantus (as they would normally do with biologics) because Lantus (and other insulins) are not approved under the Public Health Service Act. This means there is no “reference product” for Lantus to be a proposed biosimilar product.
See more with our drug comparison tool: Basaglar vs. Lantus
This is not all the information you need to know about Basaglar or Lantus for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full product information here, and discuss this information and any questions you have with your doctor or other health care provider.
Related medical questions
- Basaglar and Lantus - What is the difference between them?
- How and where should I inject insulin?
- What are the different types of insulin?
- When is the best time to take Toujeo?
- How long can Toujeo stay out of the refrigerator?
- Soliqua vs Lantus: What’s the difference between them?
- Can Toujeo be given twice a day?
- How many pens are in a box of Toujeo?
- What is the difference between Soliqua and Xultophy?
- Basaglar and Lantus - What is the difference between them?
- How and where should I inject insulin?
- When is the best time to take Toujeo?
- What are the different types of insulin?
- How long can Toujeo stay out of the refrigerator?
- Soliqua vs Lantus: What’s the difference between them?
- Can Toujeo be given twice a day?
- How many pens are in a box of Toujeo?
- What is the difference between Soliqua and Xultophy?
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions